Humana (HUM) Projected to Post Earnings on Wednesday

Humana (NYSE:HUM) will likely be posting its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Humana to post earnings of $2.95 per share and revenue of $31.9907 billion for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 6:00 AM ET.

Humana Price Performance

Shares of NYSE:HUM opened at $280.19 on Tuesday. The company’s fifty day moving average is $280.99 and its two-hundred day moving average is $258.73. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. The company has a market cap of $33.70 billion, a P/E ratio of 21.50, a price-to-earnings-growth ratio of 1.71 and a beta of 0.42. Humana has a 12-month low of $206.87 and a 12-month high of $315.35.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be issued a $0.885 dividend. The ex-dividend date is Friday, December 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.3%. Humana’s dividend payout ratio is currently 27.17%.

Institutional Investors Weigh In On Humana

A number of institutional investors have recently bought and sold shares of the business. Geneos Wealth Management Inc. boosted its stake in shares of Humana by 40.3% in the 2nd quarter. Geneos Wealth Management Inc. now owns 571 shares of the insurance provider’s stock valued at $140,000 after purchasing an additional 164 shares in the last quarter. B. Riley Wealth Advisors Inc. bought a new position in shares of Humana in the second quarter worth about $201,000. Revolve Wealth Partners LLC bought a new position in shares of Humana in the fourth quarter worth about $202,000. HUB Investment Partners LLC bought a new position in shares of Humana in the second quarter worth about $212,000. Finally, Teza Capital Management LLC lifted its position in Humana by 9.4% during the 2nd quarter. Teza Capital Management LLC now owns 1,255 shares of the insurance provider’s stock valued at $307,000 after purchasing an additional 108 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on HUM shares. Wall Street Zen lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Barclays lowered their price objective on shares of Humana from $315.00 to $245.00 and set an “equal weight” rating on the stock in a research note on Friday, October 3rd. Sanford C. Bernstein raised their price objective on shares of Humana from $269.00 to $341.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Truist Financial set a $300.00 target price on shares of Humana in a research note on Tuesday, October 14th. Finally, The Goldman Sachs Group initiated coverage on shares of Humana in a research note on Tuesday, October 14th. They issued a “sell” rating and a $235.00 target price for the company. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Humana currently has a consensus rating of “Hold” and a consensus price target of $299.22.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.